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Abstract
Hematopoietic stem cell (HSC) self-renewal is tightly controlled by cytokines and other signals in
the microenvironment. While stem cell factor (SCF) is an early acting cytokine that activates the
receptor tyrosine kinase KIT and promotes HSC maintenance, how SCF/KIT signaling is
regulated in hematopoietic stem cells is poorly understood. The protein tyrosine phosphatase 4A
(PTP4A) family [aka PRL (phosphatase of regenerating liver) phosphatases], consisting of
PTP4A1/PRL1, PTP4A2/PRL2 and PTP4A3/PRL3, represents an intriguing group of
phosphatases implicated in cell proliferation and tumorigenesis. However, the role of PTP4A in
hematopoiesis remains elusive. To define the role of PTP4A in hematopoiesis, we analyzed HSC
behavior in Ptp4a2 (Prl2) deficient mice. We found that Ptp4a2 deficiency impairs HSC self-
renewal as revealed by serial bone marrow transplantation assays. Moreover, we observed that
Ptp4a2 null hematopoietic stem and progenitor cells (HSPCs) are more quiescent and show
reduced activation of the AKT and ERK signaling. Importantly, we discovered that the ability of
PTP4A2 to enhance HSPC proliferation and activation of AKT and ERK signaling depends on its
phosphatase activity. Furthermore, we found that PTP4A2 is important for SCF-mediated HSPC
proliferation and loss of Ptp4a2 decreased the ability of oncogenic KIT/D814V mutant in
promoting hematopoietic progenitor cell proliferation. Thus, PTP4A2 plays critical roles in
regulating HSC self-renewal and mediating SCF/KIT signaling.
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INTRODUCTION
In order to maintain hematopoietic homeostasis throughout the life of an animal, the
hematopoietic stem cell (HSC) pool must be maintained through the process of self-renewal
[1]. HSC self-renewal requires the integration of survival and proliferation signals to
maintain an undifferentiated state. This demands a complex crosstalk between extrinsic
signals from the microenvironment and the cell-intrinsic regulators of HSCs [2–3]. Stem cell
factor (SCF) is a dimeric molecule that exerts its biological functions by binding to and
activating the receptor tyrosine kinase KIT [4]. KIT is highly expressed in HSCs and
SCF/KIT signaling plays a critical role in HSC maintenance [5–14]. SCF is an early acting
cytokine that promotes HSC proliferation and survival [5–8]. Studies in mice with either
partial or complete loss-of-function KIT mutations, have revealed severe hematopoietic
deficiencies of multiple lineages, as well as an important role of KIT in sustaining rapidly
cycling HSCs post transplantation when competing with wild-type HSCs [9–14]. Despite the
wealth of knowledge on SCF/KIT signaling, it is poorly understood how KIT signaling is
regulated in HSCs [4].
Gain-of-function mutations in KIT receptor in humans are associated with gastrointestinal
stromal tumors (GIST), systemic mastocytosis (SM), and acute myelogenous leukemia
(AML) [15–17]. These mutations results in altered substrate recognition and constitutive
tyrosine autophosphorylation leading to promiscuous and constitutive signaling [18–20].
Consequently, cell lines and primary bone marrow (BM) cells that express the oncogenic
KIT mutant demonstrate ligand-independent proliferation in vitro and myeloproliferative
disease (MPD) in vivo [18–22]. However, the intracellular signals that contribute to mutant
KIT-induced MPD are not known.
The PRL (Phosphatase of Regenerating Liver) phosphatases constitute a novel class of
small, prenylated phosphatases (PRL1, 2, and 3) that share a high degree (>76%) of
sequence identity [23–25]. The PRLs are relatively small proteins of about 20 kDa. In
addition to the phosphatase domain, there are no regulatory domains except that all PRLs
contain a consensus C-terminal prenylation motif CaaX, which is important for their
localization to the plasma membrane and early endosomal compartments [23–25]. This
family of phosphatases is also known as protein tyrosine phosphatase 4As (PTP4As).
PTP4A1/PRL1 was originally identified as an immediate early gene induced during liver
regeneration after partial hepatectomy [23]. Subsequently, PTP4A1/PRL1 as well as the
closely related PTP4A2/PRL2 and PTP4A3/PRL3 were found to be elevated in numerous
tumor cell lines, and cells expressing high levels of PTP4As exhibit enhanced proliferation
and anchorage-independent growth [24–29]. Unlike most protein phosphatases that
counteract the activity of protein kinases, the PTP4As play a positive role in signaling and
possess oncogenic properties [30–31]. Consistent with their oncogenic potential, we recently
revealed that PTP4A2/PRL2 promotes placenta development by downregulating PTEN,
leading to AKT activation [32].
Ptp4a2/Prl2 is located on human chromosome 1p35 [30], a region often rearranged or
amplified in malignant lymphoma and B-cell chronic lymphocytic leukemia (B-CLL) [33–
34]. While Ptp4a2/Prl2 mRNA is highly expressed in pediatric acute myeloid leukemia cells
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[35–36], its role in normal and malignant hematopoiesis is largely unknown. Here we report
a functional requirement of PTP4A2/PRL2 in hematopoietic stem cell self-renewal. We
further demonstrate that PTP4A2/PRL2 is an important mediator of SCF/KIT signaling in
HSCs.
MATERIALS AND METHODS
Mice
The generation of Ptp4a2/Prl2 knockout mice (Ptp4a2−/−, C57BL6/129P2 mixed
background) has been described previously [32]. Ptp4a2/Prl2 knockout mice were
backcrossed with C57BL6 mice for at least 8 generations. Wild type C57BL/6 (CD45.2+),
B6.SJL (CD45.1+) and F1 mice (CD45.2+ CD45.1+) mice were purchased from the Jackson
Laboratories. All mice were maintained in the Indiana University Animal Facility according
to IACUC-approved protocols, and kept in Thorensten units with filtered germ-free air.
Flow cytometry
Flow cytometry analysis of hematopoietic stem and progenitor cells was performed as
described previously [37–38]. Murine hematopoietic stem and progenitor cells were
identified and evaluated by flow cytometry using a single cell suspension of bone marrow
mononuclear cells (BMMCs). Hematopoietic stem and progenitors are purified based upon
the expression of surface markers: LT-HSC (Lin−Sca1+Kit+CD34−CD48−CD150+), ST-
HSC (Lin−Sca1+Kit+CD34+CD48+CD150+), MPP (Lin−Sca1+Kit+CD34+CD48+CD150−),
CMP (Lin−Sca1−IL7R−Kit+FcγRII/IIIlowCD34high), GMP (Lin−Sca1−IL7R−Kit+FcγRII/
IIIhighCD34high), MEP (Lin−Sca1−IL7RKit+FcγRII/IIIlowCD34low) and CLP
(Lin−IL7R+Sca1lowKitlow). BMMCs were obtained from both tibias and femurs by flushing
cells out of the bone using a syringe and DMEM plus 10% FBS. Cells were first stained
with a lineage (Lin) cocktail of antibodies from BD Biosciences (biotinylated anti-mouse
antibodies directed against CD3e, CD11b, CD45R/B220, Gr-1, Ter119) as well as Sca-1 PE
and c-KIT APC (Pharmingen), and a streptavidin Cychrome conjugate (Pharmingen). c-
KIT-APC, Sca-1-PE-Cy7, Flt3-PE, CD34-FITC and streptavidin APC-Cy7 were used for
analysis using a FACSLSR II cytometer (BD Biosciences). FITC-CD41, FITC-CD48 and
FITC-CD34 were purchased from eBioscience and PE-CD150 purchased from Biolegend
for SLAM marker analysis. All other antibodies were from BD Biosciences. For
immunophenotypic analysis, approximately 3 × 106 BMMCs were stained with antibodies
for 30 minutes on ice in dark. Nuclear staining of Ki67 was assessed by using an FITC-anti-
human Ki67 antibody (BD Pharmingen) and fixation and permeabilization solutions from
BD Biosciences. Experiments were performed on FACSAria and FACSLSR II cytometers
(BD Biosciences) and analyzed by using the FlowJo Version 9.3.3 software (TreeStar).
Bone marrow transplantation
For the competitive repopulation assays, we injected 5 × 105 BMMCs from wild type and
Ptp4a2 null mice (CD45.2+) plus 5 × 105 competitor bone marrow cells (CD45.1+) into
lethally irradiated F1 mice (CD45.1+CD45.2+). Peripheral blood was obtained by tail vein
bleeding every month, the RBC lysed, and the PBMCs stained with anti-CD45.2 FITC and
anti-CD45.1 PE, and analyzed by flow cytometry. 16 weeks following transplantation, we
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harvested bone marrow cells from mice reconstituted with wild type or Ptp4a2 null bone
marrow cells and transplanted 3 × 106 bone marrow cells into lethally irradiated F1 mice
(CD45.1+CD45.2+).
For HSC transplantation, we injected 200 CD48−CD150+KSL cells from wild type or
Ptp4a2 null mice (CD45.2+) plus 3 × 105 competitor bone marrow cells (CD45.1+) into
lethally irradiated F1 mice (CD45.1+CD45.2+). Peripheral blood was obtained by retro-
orbital eye bleeding every month, the RBC lysed, and the PBMCs stained with anti-CD45.2
FITC and anti-CD45.1 PE, and analyzed by flow cytometry. 16 weeks following
transplantation, we harvested bone marrow cells from recipient mice and performed flow
cytometry analysis to evaluate HSC repopulating capability.
Homing assays
The homing ability of wild type and Ptp4a2 null HSPCs were analyzed in irradiated
recipient mice. 1 × 107 wild type or Ptp4a2 null bone marrow cells (CD45.2+) were injected
into lethally irradiated recipient (CD45.1+) mice. Bone marrow cells were harvested 18
hours following injection and donor-derived cells were evaluated by flow cytometry as
CD45.2+ cells, simultaneously identifying Lin−Sca1+CD150+ cells.
Stem and progenitor cell assays
Clonogenic progenitors were determined in methylcellulose medium (MethoCult GF
M3234, StemCell Technologies) with cytokines (SCF, TPO, EPO, IL-3 and GM-CSF) using
2 × 104 BMMCs per well (6-well plate). Colonies were scored after 7 days of the initial
culture, and all cells were collected and washed twice in phosphate-buffered saline.
Subsequently cells were cultured at 2 ×104 per well in the same medium. Colony scoring
and replating were repeated every 7 days for at least two times, or until no colonies were
observed in the cultures.
Immunoblotting
Cells were washed with ice-cold phosphate-buffered saline, and lysed on ice for 30 min in
lysis buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1% Triton X-100, 10% glycerol)
supplemented with protease inhibitor (Roche) and phosphatase inhibitor (Roche). Cell
lysates were cleared by centrifugation at 13,200 rpm for 10 min, and boiled with Laemmli
(SDS)-sample buffer, separated by SDS-PAGE, transferred electrophoretically to a
nitrocellulose membrane, and immunoblotted with pAKT (Cell Signaling), AKT (Cell
Signaling), pERK1/2 (Cell Signaling), ERK1/2 (Cell Signaling), PTEN (Cell Signaling),
PTP4A2/PRL2 (a generous gift from Dr. Qi Zeng) and β-Actin (Santa Cruz) followed by
incubation with horseradish peroxidase-conjugated secondary antibodies. The blots were
developed by the enhanced chemiluminescence technique using the SuperSignal West Pico
Chemiluminescent substrate (Pierce) or SuperSignal West Femto Maximum Sensitivity
Chemiluminescent Substrate (Pierce). Data shown are representation of multiple repeat
experiments.
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Statistical analysis
We used either student t test or Two-way ANOVA to determine statistical significance. *p <
0.05; **p < 0.01; ***p < 0.001; ns, not significant.
RESULTS
Ptp4a2 deficiency results in inefficient hematopoiesis
To investigate the role of PTP4A2 in hematopoiesis, we analyzed the peripheral blood and
bone marrow of 8 to 12 week-old wild type and Ptp4a2−/− mice. Ptp4a2−/− mice show
decreased white blood cell, neutrophil and lymphocyte counts, whereas hemoglobin levels
are normal in the peripheral blood (Supplementary Fig. 1A). While Ptp4a2 null mice show
decreased body size as we previously reported (Supplementary Fig. 1B) [32], the bone
marrow cellularity is normal when normalized to total body weight (supplementary Fig. 1C).
We also found that Ptp4a2−/− mice have smaller spleen and thymus compared with wild
type mice (Supplementary Fig. 2). These data indicate that PTP4A2 plays an important role
in hematopoiesis.
Ptp4a2 null mice have normal number of immunophenotypic hematopoietic stem cells
While Ptp4a1 and Ptp4a2 are broadly expressed in adult tissues including liver [25, 39–40],
the expression pattern of these Ptp4as in the hematopoietic system is unknown. We
examined the expression of Ptp4a1, Ptp4a2 and Ptp4a3 during different stages of
hematopoietic stem cell differentiation by using real-time RT-PCR assays. Ptp4a1 and
Ptp4a2 are ubiquitously expressed in the hematopoietic compartment, whereas Ptp4a3
expression is most pronounced in megakaryocyte-erythroid progenitor cells (MEPs). Ptp4a2
is highly expressed in hematopoietic cells and its expression is enriched in differentiated
cells compared to long-term HSCs and committed progenitor cells, suggesting that it could
play an important role in lineage commitment (Fig. 1A). We then examined the number of
primitive hematopoietic stem/progenitor cells in the bone marrow of Ptp4a2−/− mice. Loss
of Ptp4a2 slightly increased the frequency (*p<0.05, n=9; Fig. 1B), but not the absolute
number of Kit+Sca1+Lin− cells (KSLs) compared to wild-type mice (Fig. 1C); however,
Ptp4a2 deficiency neither affects the frequency nor the absolute number of long-term HSCs
(LT-HSCs) based on SLAM and CD34 expression (Fig. 1D, 1E). Thus, loss of Ptp4a2 does
not affect immunophenotypic HSCs.
Ptp4a2 deficiency impairs the long-term repopulating ability of HSCs
To examine whether Ptp4a2 deficiency affects HSC function, we performed serial
competitive bone marrow transplantation assays. Equal numbers of donor and competitor
bone marrow mononuclear cells (BMMCs) were transplanted into lethally irradiated
recipient mice. Sixteen weeks after primary transplantation, the repopulating ability of
Ptp4a2 null cells was significantly lower than wild-type cells (**p<0.01, n=7; Fig. 2A).
Moreover, we found that the percentage of donor-derived T cells was significantly decreased
in mice transplanted with Ptp4a2 null cells than that with wild-type cells (11.0 ± 1.9% vs.
4.1 ± 1.7% at 16 weeks, Fig. 2B). Analysis of the bone marrow revealed a striking reduction
in the number of phenotypically defined HSCs in the recipients repopulated with Ptp4a2
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null bone marrow cells (**p<0.01, n =5; Fig. 2C). We then transplanted 3 × 106 BMMCs
isolated from the primary recipient mice repopulated with wild-type or Ptp4a2 null cells into
lethally irradiated secondary recipients. Sixteen weeks after transplantation, Ptp4a2 null
cells continued to show decreased repopulating ability (***p<0.001, n=7; Fig. 2D).
To further establish that the self-renewal defect is HSC intrinsic, we purified wild-type and
Ptp4a2 null LT-HSCs (CD48−CD150+KSLs) and transplanted 200 of each into lethally
irradiated recipient mice along with 300,000 wild-type competitor BMMCs. In this context,
Ptp4a2 null HSCs exhibited a substantially lower contribution to peripheral blood
production compared to control HSCs (***p<0.001, n=7; Fig. 2E), demonstrating that
Ptp4a2 plays an important role in HSC maintenance and loss of Ptp4a2 impairs HSC self-
renewal.
The decreased self-renewal of Ptp4a2 null HSCs in transplantation assays could be due to
abnormalities in homing following transplantation. To determine whether Ptp4a2 null bone
marrow cells are defective in homing, we performed homing assays and observed similar
numbers of donor-derived Lin−Sca-1+Slam+ cells from the bone marrow of recipient mice
repopulated with wild-type or Ptp4a2 null bone marrow cells (Supplementary Fig. 3A),
suggesting the absence of homing defects. The impaired HSC self-renewal in Ptp4a2 null
mice could also be due to increased apoptosis. Therefore, we evaluated HSC survival by
Annexin-V staining and observed no significant difference in the number of apoptotic HSCs
(Annexin-V+/PI−CD48−KSLs) in the absence of cytokines (Supplementary Fig. 3B). Thus,
the impaired self-renewal of Ptp4a2 null HSC is likely due to an inability to properly self-
renew, rather than homing defects or an increase in apoptosis.
PTP4A2 promotes hematopoietic stem and progenitor cell proliferation
To assess the effect of Ptp4a2 deficiency on proliferation, we stained Ptp4a2 null
hematopoietic stem and progenitor cells with proliferation marker Ki67. While we detected
normal number of Ki67 negative LT-HSCs, we found more Ki67 negative multipotent
progenitor cells (MPPs) than normal (**p<0.01, n=6; Fig. 3A), indicating Ptp4a2 null MPPs
are more quiescent and less proliferative. We then performed methylcellulose colony-
forming unit (CFU) assays to quantify myeloid progenitor cells. While Ptp4a2 deficiency
does not affect the total number of colonies formed, Ptp4a2 null bone marrow cells formed
significantly fewer immature GEMM colonies compared with wild type cells (*p<0.05, n=3;
Fig. 3B). Consistent with the cell cycle data, Ptp4a2 null BMMCs show decreased replating
potential compared to wild-type cells (**p<0.01, n=3; Fig. 3C), further demonstrating that
hematopoietic progenitor cells show decreased proliferation in the absence of Ptp4a2. To
decipher the molecular mechanisms underlying the HSPC proliferation defects seen in the
Ptp4a2 null mice, we examined the expression of several known HSC regulators by using
real time RT-PCR assays. Several negative regulators of cell cycle, including p21 and p57,
are upregulated in Ptp4a2 null HSCs and MPPs respectively (**p<0.01, n=3; Fig. 3D, 3E).
In addition, the expression of Cyclin D1 (CCND1) and Cyclin E1 (CCNE1) are
downregulated in MPPs (**p<0.01, n=3; Fig. 3E). We further confirmed the changes in p57
and CCND1 expression in MPPs by flow cytometry (Supplementary Fig. 4).
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The ability of PTP4A2 to enhance hematopoietic progenitor cell proliferation depends on
its phosphatase activity
While we showed that PTP4A2 is important for hematopoietic progenitor cell proliferation,
whether this effect depends on its phosphatase activity is not clear. To this end, we
overexpressed wild-type or the catalytic inactive mutant form of Ptp4a2 (Ptp4a2/C101S) in
Lin− cells isolated from wild-type and Ptp4a2 null mice and performed colony forming unit
(CFU) assay [41]. While both wild-type and Ptp4a2 null mononuclear cells form similar
number of colonies in CFU assays (Fig. 3B), Ptp4a2 null Lin-Sca1+ cells formed
significantly fewer colonies compared with wild-type cells following retroviral transduction
(*p<0.05, n=3; Fig. 4A). Lin-Sca1+ cells are enriched for hematopoietic stem and progenitor
cells and we showed that Ptp4a2 null progenitor cells are less proliferative (Fig. 3A).
Therefore, the difference between the two CFU assays we observed is likely due to distinct
composition of cells used in the experiments. Ectopic expression of wild-type or mutant
Ptp4a2 did not affect the colony forming potential of wild-type cells. However, we found
that overexpressing wild-type Ptp4a2, but not the mutant form, significantly increase the
colony formation of Ptp4a2 null cells (**p<0.01, n=3; Fig. 4A). We also overexpressed
wild-type or the mutant form of Ptp4a2 in Lin− cells isolated from wild-type and Ptp4a2
null mice and monitored their proliferation. Consistent with data in the CFU assays (Fig.
4A), mock-transduced Ptp4a2 null Lin− cells show decreased proliferation compared with
that of mock-transduced wild type cells (**p<0.01, n=3; Fig. 4B). Wild-type Ptp4a2
transduced Ptp4a2 null cells showed enhanced proliferation compared with mock and
mutant Ptp4a2 transduced cells (**p<0.01, n=3; Fig. 4B).
To decipher the molecular mechanisms underlying the HSPC proliferation defects seen in
the Ptp4a2 null mice, we examined the activation of AKT and ERK signaling in freshly
purified Lin− cells. We observed that the levels of pAKT and pERK1/2 are significantly
lower in Ptp4a2 null Lin- cells compared with those in wild-type cells (Fig. 4C). To
investigate the mechanism by which Ptp4a2 deficiency attenuates AKT and ERK activation,
we analyzed PTEN (phosphatase and tensin homologue deleted on chromosome ten)
expression in both wild-type and Ptp4a2 null cells. PTEN is an antagonist of PI3K signaling
pathway [42]. In addition, PTEN has also been shown to negatively regulate the activation
of the ERK pathway [42]. We previously reported that in placenta, Ptp4a2 deficiency led to
elevated PTEN expression [32]. To examine whether this is also the case in HSPCs, we
measured PTEN protein level in wild-type and Ptp4a2 null Lin- cells. As shown in Figure
4C, PTEN expression was 1.4 ± 0.15 fold higher in Ptp4a2 null samples, consistent with our
previous observation in placenta [32]. Therefore, impaired AKT and ERK activation in
Ptp4a2 null Lin- cells is likely due to increased PTEN level. Furthermore, we found that
expression of wild-type Ptp4a2, but not the catalytically inactive mutant Ptp4a2,
significantly augments pAKT and pERK1/2 levels in Ptp4a2 null Lin− cells (Fig. 4D and
Supplementary Fig. 5), demonstrating that the ability of PTP4A2 to promote hematopoietic
progenitor cell proliferation and activation of AKT and ERK signaling depends on its
phosphatase activity.
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PTP4A2 is important for SCF/KIT signaling in hematopoietic stem and progenitor cells
Given that Ptp4a2 null bone marrow mononuclear cells show decreased colony formation in
serial replating assays, PTP4A2 may play an important role in cytokine signaling. To test
this hypothesis, we cultured both wild-type and Ptp4a2 null Kit+ cells in the presence or
absence of cytokines, including SCF, G-CSF and IL-3, and monitored their proliferation.
While wild-type and Ptp4a2 null Kit+ cells exhibited similar proliferative behaviors in
response to G-CSF or IL-3 stimulation, Ptp4a2 null hematopoietic progenitor cells showed
decreased proliferation in response to SCF (*p<0.05, n=3; Fig. 5A). In CFC assays, Ptp4a2
null KSL cells formed significantly fewer colonies compared with wild-type KSL cells in
response to SCF stimulation (**p<0.01, n=3; Fig.5B). Importantly, Ptp4a2 null KSL cells
showed marked reduction of GEMM colony formation in response to decreased
concentration of SCF compared with wild-type KSL cells, demonstrating that PTP4A2 is
essential for the proliferation of hematopoietic progenitor cells following SCF stimulation.
We then examined whether Ptp4a2 deficiency affects HSPC survival in the absence of
cytokine. As shown in Figure 5C, Ptp4a2 null Kit+ cells showed decreased cell counts
compared with wild-type cells (*p<0.05, n = 3), indicating that PTP4A2 is essential for
HSPC survival in the absence of cytokine. Furthermore, we observed that the levels of
pAKT and pERK1/2 are also significantly lower in Ptp4a2 null Kit+ cells compared with
those in wild-type cells in the basal state (Figure 5D). Stimulation of HSPCs with SCF can
activate several signaling pathways through KIT, including PI3K/AKT and ERK1/2
pathways [4–6]; therefore, it is possible that Ptp4a2 deficiency impairs the activation of
these signaling pathways in response to SCF stimulation. This is indeed the case, as Ptp4a2
null cells displayed decreased activation of both pAKT and pERK1/2 at 30 minutes
following SCF stimulation (Figure 5D), demonstrating that PTP4A2 is important for
sustaining SCF signaling in hematopoietic stem and progenitor cells.
PTP4A2 is important for oncogenic KIT signaling in hematopoietic progenitor cells
Hematopoietic cell lines and primary BM cells expressing the oncogenic KIT/D814V
mutant display ligand-independent proliferation in vitro and myeloproliferative disease
(MPD) in vivo [18–22]. Based on our finding that PTP4A2 is important for SCF/KIT
signaling in HSPCs, we speculated that PTP4A2 may also enhance KIT/D814V-mediated
ligand-independent hyperproliferation and activation of signaling pathways. To test this, we
introduced wild-type KIT and KIT/D814V mutant into Lin− cells purified from wild-type
and Ptp4a2 null mice and performed serial replating assays. In primary (*p<0.05, n=3),
secondary (**p<0.01, n=3) and tertiary replating experiments (***p<0.001, n=3), Ptp4a2
null Lin− cells expressing KIT/D814V formed significantly fewer colonies compared with
wild-type Lin− cells expressing the KIT mutant (Fig. 6A). Both wild-type and Ptp4a2 null
cells expressing wild-type KIT did not form any colonies in the tertiary replating
experiments (Fig. 6A). To determine whether PTP4A2 is essential for KIT/D814V-mediated
ligand-independent growth, we cultured Ptp4a2 wild-type and null cells expressing wild-
type or KIT/D814V in the absence of cytokine or the presence of SCF. As shown in Figure
6B (**p<0.01, n=3), Ptp4a2 deficiency significantly decreased the ability of KIT/D814V to
promote cell proliferation both in the absence and presence of SCF. Furthermore, we
observed decreased phosphorylation of AKT and ERK1/2 in Ptp4a2 null cells expressing
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KIT/D814V mutant compared with wild-type cells (Figure 6C). Thus, PTP4A2 is essential
for KIT/D814V-mediated hematopoietic progenitor cell hyperproliferation and activation of
signaling pathways.
DISCUSSION
The PTP4A family of phosphatases, consisting of PTP4A1, PTP4A2, and PTP4A3,
represents an intriguing group of proteins implicated as biomarkers and therapeutic targets
in cancer [23–25]. Individual PTP4As are overexpressed in a variety of cancer cell lines and
tissues when compared with their normal counterparts [26–29]. However, the exact
biological functions of PTP4As are largely unknown [23–25]. Herein we report that
PTP4A2/PRL2 plays a critical role in hematopoietic stem cell self-renewal and SCF/KIT
signaling.
While loss of Ptp4a2/Prl2 modestly increased the frequency of multipotent progenitor cells,
Ptp4a2 deficiency does not affect immunophenotypic hematopoietic stem cell numbers. To
further define the role of PTP4A2 in regulating hematopoietic stem cell self-renewal, we
performed serial bone marrow transplantation assays and found that loss of Ptp4a2 impairs
the ability of hematopoietic stem cells to repopulate the lethally irradiated recipient mice.
These observations were confirmed by HSC transplantation. Furthermore, we observed no
homing defects following transplantation and no increased HSC apoptosis, demonstrating
that PTP4A2 functions as a positive regulator of hematopoietic stem cell self-renewal. We
also found that the percentage of donor-derived T cells was significantly lower in mice
transplanted with Ptp4a2 null cells than that with wild-type cells, indicating that PTP4A2
may also regulate T cell differentiation under stress conditions.
Among the signal transduction pathways that have attracted considerable attention as
possibly being involved in HSC maintenance is the phosphoinositide 3-kinase (PI3K)-AKT
pathway [43]. As an antagonist of the PI3K pathway, PTEN has been implicated as a
regulator of HSC self-renewal and loss of PTEN in the HSC compartment results in
hyperproliferation of hematopoietic stem and progenitor cells [44]. Recently, we showed
that in mouse placenta PTP4A2/PRL2 promotes cell proliferation by activating the AKT
kinase through downregulation of the tumor suppressor PTEN [32]. It appears that Ptp4a2
overexpression enhances the degradation of PTEN protein in these cells, indicating that
PTP4A2/PRL2 regulates the stability of PTEN in placenta [32]. In addition, we observed
that loss of Ptp4a2 decreases hematopoietic stem and progenitor cell proliferation and
Ptp4a2 null hematopoietic progenitor cells show decreased phosphorylation of AKT and
ERK1/2 in steady state. To investigate how PTP4A2 regulates PI3K/AKT signaling in
hematopoietic progenitor cells, we examined the level of PTEN in Ptp4a2 null HSPCs. As
seen in placenta, we observed moderate but statistically significant elevation of PTEN
protein in Ptp4a2 null HSPCs compared to that in wild-type HSPCs, whereas PTEN RNA
level is identical between Ptp4a2 wild-type and null cells. Therefore, it is possible that
PTP4A2 regulates the stability and turnover of PTEN protein in hematopoietic stem and
progenitor cells as well. PTEN has been shown to regulate cell proliferation and cancer
progression in a dosage-dependent manner and a slight reduction in PTEN levels dictates
cancer susceptibility [45–46]. Thus, it is likely that increased level of PTEN we observed
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contributes to the decreased activation of AKT and ERK1/2 signaling pathways in Ptp4a2
null HSPCs. Moreover, consistent with PTEN's established role in sustaining HSPC
proliferation, our data suggest that increased PTEN expression in Ptp4a2 deficient mice
leads to reduced proliferation of HSPCs.
Ectopic expression of Ptp4a2 in nontumorigenic cells has been shown to enhance cell cycle
progression and promotes proliferation [28, 36]. This process may be dependent on the
down-regulation of cyclin dependent kinase inhibitor p21 [28]. The cell cycle defects seen in
Ptp4a2 null mice may also be mediated by cell cycle regulators as we observed decreased
expression of p21 and p57 in hematopoietic stem and progenitor cells. Both p21 [47] and
p57 [48] have been shown to regulate HSPC proliferation; therefore, PTP4A2 plays an
important role in promoting HSPC proliferation, at least in part by controlling the level of
cell cycle regulators. How PTP4A2 regulates the expression of these cell cycle regulators is
not clear. However, we note that PTEN controls cell cycle entry and progression through
inhibiting PI3K-AKT activity [49–50] and PTEN loss leads to enhanced G0–G1 cell cycle
transition, which yields a short-term expansion of HSCs [43].
Given that Ptp4a2 null hematopoietic progenitor cells show decreased colony formation in
serial replating assays, it is possible that PTP4A2 regulates cytokine signaling in
hematopoietic progenitor cells. While Ptp4a2 null hematopoietic progenitor cells proliferate
normally in response to IL-3 or G-CSF stimulation, these cells are less proliferative in
response to SCF stimulation. Furthermore, Ptp4a2 null hematopoietic progenitor cells show
decreased colony formation in response to increased concentrations of SCF compared with
wild-type cells. The role of PTP4A2 in mediating SCF/KIT signaling appears modest, as
SCF still activates a remarkable amount of AKT and ERK in Ptp4a2 null cells (Fig. 5D).
Therefore, PTP4A2 may be one of many factors that contribute to KIT function in
hematopoietic stem and progenitor cells.
As the receptor for SCF, the biologic significance of KIT in hematopoiesis was first revealed
in the white spotting (W) mutant mice [51]. Several W mutations with different levels of KIT
kinase deficiency were found to correlate with the phenotype severity [9–14]. Studies in the
viable primary W mutant mice or in mice after transplantation indicate the importance of
KIT signaling in maintaining HSC quiescence and survival [9–14]. The hematopoietic
defects seen in the Ptp4a2 null mice recapitulate some hematopoietic phenotype of KIT
mutant mice, providing additional evidence that PTP4A2 plays an important role in
mediating SCF/KIT signaling in hematopoietic progenitor cells.
While Ptp4a2 is highly expressed in acute myeloid leukemia cells [35–36], its role in
leukemogenesis is largely unknown. We discovered that loss of Ptp4a2 decreased the ability
of KIT/D814V mutant in promoting hematopoietic progenitor cell proliferation,
demonstrating that PTP4A2 is an important effector molecule of oncogenic KIT signaling in
hematopoietic stem and progenitor cells and positively contributes to KIT/D814V-induced
hematopoietic progenitor hyperproliferation. Therefore, pharmacological inhibition of
PTP4A2 in KIT/D814V-expressing cells in vivo could delay leukemia progression and
decrease the severity of the disease.
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CONCLUSION
In summary, this study reveals a critical role of PTP4A2/PRL2 in hematopoietic stem cell
self-renewal and SCF/KIT signaling. Our results suggest that the PTP4A2 phosphatase may
be a druggable target in myeloproliferative disease (MPD) and acute myeloid leukemia
(AML) with oncogenic KIT mutations.
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Figure 1.
Ptp4a2 null mice have normal number of immunophenotypic hematopoietic stem cells. (A):
Real-time RT-PCR analysis of Ptp4a mRNAs in long-tern HSCs (LTHSCs), short-term
HSCs (ST-HSCs) and representative committed progenitors and differentiated cells. MPPs,
multi-potential progenitors; CLPs, common lymphoid progenitors; CMPs, common myeloid
progenitors; MEPs, megakaryocyte-erythroid progenitors; GMPs, granulocyte-macrophage
progenitors. Data shown are the mean values ± SD (n = three biological replicates). (B): The
frequency of Kit+Sca1+Lin− cells (KSLs) were quantified by flow cytometry. Data shown
are the mean percentage (± SD) of KSL cells in the bone marrow (*p<0.05, n=9). (C): The
absolute number of KSLs per femur is shown. Graphs represent the mean ± SD (n=9). (D):
The frequency of LT-HSCs (CD34−CD48−CD150+KSLs) was defined by flow cytometry
analysis of SLAM cell surface markers. Data shown are the mean percentage (± SD) of LT-
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HSCs in the bone marrow (n=9). (E): The absolute number of LT-HSCs per femur is shown.
Graphs represent the mean ± SD (n=9).
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Figure 2.
Ptp4a2 deficiency impairs the long-term repopulating ability of HSCs. (A): Lethally
irradiated recipient mice (CD45.1+ and CD45.2+) were transplanted with 5 × 105 bone
marrow mononuclear cells (BMMCs) from wild-type and Ptp4a2 null mice (CD45.2+) plus
5 × 105 competitor cells (CD45.1+) in competitive repopulation assays. Graph shows the
mean percentage (±SD) of donor-derived (CD45.2+) cells in the peripheral blood
posttransplantation, measured at monthly intervals (**p<0.01, n = 7). (B): Contribution of
donor-derived cells (CD45.2+) from A, for myeloid cells (Gr1+), B cells (B220+) and T cells
(CD3+) in peripheral blood from recipient mice at different time points after transplantation
(*p<0.05, n = 7). (C): Quantification of donor-derived (CD45.2+) HSC frequency in the
bone marrow of primary recipient mice 18 weeks following transplantation by three
phenotypic definitions. Mean ± SD values are shown (**p<0.01, n = 5). (D): Contribution of
wild type and Ptp4a2 null bone marrow mononuclear cells (BMMCs) to recipient mouse
peripheral blood in secondary competitive transplants, measured at monthly intervals
(***p<0.001, n = 7). (E): Lethally irradiated recipient mice (CD45.1+ and CD45.2+) were
transplanted with 200 LT-HSCs (CD48−CD150+KSLs) from wild-type and Ptp4a2 null
mice (CD45.2+) plus 3 × 105 competitor cells (CD45.1+) in competitive repopulation assays.
Graph shows the mean percentage (±SD) of donor-derived (CD45.2+) cells in the peripheral
blood posttransplantation, measured at monthly intervals (***p<0.001, n = 7).
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Figure 3.
PTP4A2 regulates hematopoietic stem and progenitor cell proliferation. (A): Cell-cycle
analysis of hematopoietic stem and progenitor cells was performed by staining with DAPI
and Ki67 and analyzed by FACS. Data shown are the mean values ± SD (**p<0.01, n = 6).
(B): Myeloid progenitors were quantified by methylcellulose culture using bone marrow
mononuclear cells from wild-type and Ptp4a2 null mice (*p<0.05, n = 3). (C): Serial
replating studies. Myeloid progenitors were quantified by methylcellulose culture using
BMMCs from wild-type and Ptp4a2 null mice. The methylcellulose cultures were serially
replated, weekly, for 3 weeks. Mean values (±SD) are shown (**p<0.01, n = 3). (D and E):
Ptp4a2 deficiency results in upregulation of cell cycle regulators in HSCs (D) and MPPs
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(E). Real-time RT-PCR analysis of some known HSC regulators in LT-HSCs and MPPs.
Data shown are the mean values ± SD (**p<0.01, n = three biological replicates).
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Figure 4.
The ability of PTP4A2 to enhance hematopoietic progenitor cell proliferation depends on its
phosphatase activity. (A): Myeloid progenitors were quantified by methylcellulose culture
using wild type and Ptp4a2 null Lin-Sca1+ cells transduced with retroviruses expressing the
WT or the mutant form (Ptp4a2/C101S) of Ptp4a2. Data are means ± SD (**p<0.01, n = 3
independent experiments). (B): Proliferation of wild type and Ptp4a2 null Lin− cells
expressing the WT or the mutant form (Ptp4a2/C101S) of Ptp4a2 in response to SCF
stimulation. Data are means ± SD (**p<0.01, n = 3 independent experiments). (C):
Immunoblot analysis of AKT and ERK phosphorylation in freshly purified wild type and
Ptp4a2 null Lin− cells. *p < 0.05 compared with wild type cells by one-way analysis of
variance (ANOVA) and Bonferroni post hoc test, n= three independent experiments.
Representative Western blot analysis of indicated proteins is shown. (D): Immunoblot
analysis of AKT and ERK phosphorylation in Ptp4a2 null Lin− cells expressing the WT or
the mutant form (Ptp4a2/C101S) of Ptp4a2. *p < 0.05 compared with mock transduced cells
by one-way analysis of variance (ANOVA) and Bonferroni post hoc test, n= three
independent experiments. Representative Western blot analysis of indicated proteins is
shown. .
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Figure 5.
PTP4A2 is important for SCF/KIT signaling in hematopoietic stem and progenitor cells.
(A): Proliferation of wild type and Ptp4a2 null Kit+ cells in response to cytokine
stimulation. Data shown are the mean values ± SD (*p<0.05, n = 3). (B): Colony Forming
Unit (CFU) assays in the presence of increased concentration of SCF. Data shown are the
mean values ± SD (**p<0.01, n = 3). (C): Proliferation of wild type and Ptp4a2 null Kit+
cells in the absence of cytokines. Data shown are the mean values ± SD (*p<0.05, n = 3).
(D): Immunoblot analysis of AKT, and ERK phosphorylation in wild type and Ptp4a2 null
Kit+ cells following SCF stimulation. Data represent three independent experiments.
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Figure 6.
PTP4A2 is important for oncogenic KIT signaling in hematopoietic progenitor cells. (A):
Myeloid progenitors were quantified by methylcellulose culture in the presence of SCF
using wild type and Ptp4a2 null Lin− cells transduced with retroviruses expressing the WT
or the mutant form (KIT/D814V) of KIT. The methylcellulose cultures were serially
replated, weekly, for 3 weeks. Data are means ± SD (*p<0.05, **p<0.01, ***p<0.001, n = 3
independent experiments). (B): Proliferation of wild type and Ptp4a2 null Lin− cells
expressing the WT or the mutant form (KIT/D814V) of KIT in the presence or the absence
of cytokine stimulation. Data are means ± SD (**p<0.01, n = 3 independent experiments).
(C): Immunoblot analysis of AKT and ERK phosphorylation in wild type and Ptp4a2 null
Lin− cells expressing the WT or the mutant form (KIT/D814V) of KIT in response to SCF
stimulation. Data represent three independent experiments.
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